Feature | Radiation Oncology | May 29, 2019 | By Jeff Zagoudis

Recent research and commercial efforts demonstrate the possibilities of using MRI scans to reconstruct CT imaging for treatment planning without additional patient exposure

A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing  synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of  the anatomy.

A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of the anatomy.

Computed tomography (CT) has traditionally played an important role in the development of radiation therapy treatment plans for cancer patients. The Hounsfield unit measurements acquired from a CT scan are critical for therapeutic dose calculations to ensure that the most dose is delivered to the target region, while sparing healthy tissue as much as possible. Aside from dose calculation, however, CT has inherent limitations that require the use of other modalities like magnetic resonance imaging (MRI) to generate a complete, optimal treatment plan.

In these scenarios, the two image sets must be coregistered in order to display the most complete picture with all of the information needed for planning. Coregistration comes with its own set of uncertainties, however, over the images not being aligned correctly. Moreover, this methodology still utilizes CT, exposing the patient to even more radiation dose when they are already receiving a large therapeutic dose.

It is for these reasons that clinicians and vendors throughout the industry have been looking for new imaging methods that might resolve all of these issues. One avenue that has shown promise in recent years is the creation of synthetic CT images from an MR-only imaging sequence. “It’s more efficient, [with] fewer things to contour and coregister, so we expect coregistration uncertainty to be reduced by having only one imaging modality, which is the one that is most desirable for a lot of disease sites,” said Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System in Detroit.


New Research Arenas in Synthetic CT

Glide-Hurst and her colleagues at Henry Ford have spent the last several years exploring new applications for synthetic CT in treatment planning, as well as ways to enhance the utility of the technology. One area they have focused on in particular is deriving the CT Hounsfield units needed for therapeutic dose calculation from MRI-based synthetic CT.

Glide-Hurst credited junior physicist Joshua Kim, Ph.D., for a prostate cancer-specific solution to enhance synthetic CT dose calculation. “Essentially what it is, our prostate solution relies on a T1 and T2 input dataset, and then it’s a voxel-based weighted summation and it’s got patient-specific output. It gives a very good agreement to the CT both in the bones and the tissue and all of the different soft tissue,” Glide-Hurst said.

The Henry Ford group has also taken interest in using synthetic CT for brain cancer treatment planning, particularly for image-guided radiation therapy (IGRT), where the application is not as well understood. “The brain is a little trickier because we have to worry about some small bones and small structures, and a much more complex anatomy there. Accuracy is very, very important in the brain,” said Glide-Hurst.

A 2018 study by the group compared geometric equivalence of digitally reconstructed radiographs (DRRs) from CTs and synthetic CTs to quantify performance for partial brain image-guided radiation therapy (IGRT). For the study, 10 brain cancer patients underwent both MRI and CT simulation. Synthetic CTs were generated by combining ultra-short echo time, T1, T2 and fluid attenuation inversion recovery datasets using voxel-based weighted summation. The two types of DRRs were compared using patient-specific thresholding and assessed using:

•    Overlap index;

•    Dice similarity coefficient; and

•    Jaccard index.


Planar IGRT images for 22 fractions were evaluated for differences between the two DRR types in six quadrants. Ultimately, statistically significant differences between CT and synthetic CT registrations were observed in 9 of 18 matched quadrants/axes. The researchers concluded that while the DRR synthetic CT geometry was robust, the results were not clinically significant.1


Commercial Synthetic CT Products

As the technology continues to prove valuable, vendors from both the imaging and treatment planning sides have begun releasing their own synthetic CT products.

Siemens Healthineers introduced synthetic CT capabilities on the Magnetom RT Pro edition of the Magnetom Sola MRI scanner, debuting at the 2018 American Society of Radiation Oncology (ASTRO) meeting. The 1.5T scanner has multiple new features tailored specifically for treatment planning, highlighted by RT Image Suite, a dedicated post-planning software. Synthetic CT capabilities of the RT Image Suite address five major areas:

•    Imaging for planning and simulation: The
    scanner’s RT Dot Engine provides workflow
    guidance during image acquisition, with
    dedicated RT protocols for brain, head and
    neck, and pelvis exams.

•    Post-processing and assessment: After
    acquisition, the synthetic CT image is
    automatically created and displayed on the
    scanner console.

•    Contouring: The system displays the synthetic
    CT alongside other MR images for patient
    marking, assessment and parallel contouring.
    Once this step is complete, the synthetic image
    can be exported to the treatment planning
    system for dose calculation.

•    Dosimetric planning: Users can correlate the
    synthetic CT dose calculations with
    conventional CT to check agreement.

•    Treatment monitoring and adaptation: Siemens
    included a variety of applications that can aid
    in assessing treatment response alongside
    synthetic CT images, including MR OncoCare
    for functional characteristics of a lesion.


On the treatment planning side, Sweden-based Spectronic Medical received European CE mark in 2016 for its MRIPlanner software. The software facilitates the creation and transfer of synthetic CT images between the MRI scanner and the treatment planning system (TPS). A LinkClient DICOM node installed at the hospital receives the original MR images from the scanner and forwards them to the MRIPlanner software. Upon completion, the node returns the synthetic image with the proper delineations to the TPS.

A 2017 study published in the International Journal of Radiation Oncology Biology Physics demonstrated that the MR-only workflow of MRIPlanner was dosimetrically accurate and robust for a variety of equipment vendors, magnetic field strengths and treatment techniques. Mean dose differences between the CT and synthetic CT images in the MR-OPERA study were below 0.25 percent for all evaluated organ and target structures; gamma evaluation showed a mean pass rate of 99.12 percent in complete body volume and 99.97 percent in the planning target volume. Results were consistent across the four centers participating in the study.2

The first 30 clinical patients were treated with MRI Planner in January 2018. Spectronic Medical said that research is ongoing to explore applications for MRIPlanner in brain and head and neck cancer cases. The software has yet to receive U.S. Food and Drug Administration (FDA) approval.



1. Morris E.D., Price R.G., Kim J., et al. Using synthetic CT for partial
    brain radiation therapy: Impact on image guidance. Practical
    Radiation Oncology, September-October 2018. Published first
    online April 6, 2018. https://doi.org/10.1016/j.prro.2018.04.001


2. Persson E., Gustafsson C., Nordström F., et al. MR-OPERA: A
    Multicenter/Multivendor Validation of Magnetic Resonance
    Imaging–Only Prostate Treatment Planning Using Synthetic
    Computed Tomography Images. Red Journal, June 15, 2017


Related content:

Find more radiology and radiation oncology content from Henry Ford Hospital

Find cardiology program-related Henry Ford Hospital content

Related Content

News | Proton Therapy

August 19, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time August 19, 2022
News | Breast Imaging

August 19, 2022 — The Christ Hospital Health Network, known for providing the best, most compassionate care for its ...

Time August 19, 2022
News | Radiation Therapy

August 19, 2022 — Recently published research out of VCU Massey Cancer Center demonstrated that cancer patients who live ...

Time August 19, 2022
News | Prostate Cancer

August 16, 2022 — A new study published by University of Kentucky Markey Cancer Center researchers suggests that the ...

Time August 16, 2022
News | Breast Imaging

August 15, 2022 — Brainlab announced the first group of breast cancer patients treated in United States with the ...

Time August 15, 2022
Feature | Radiology Business | By Melinda Taschetta-Millane

Did you know that Imaging Technology News (ITN) maintains more than 40 comparison charts of product specifications from ...

Time August 12, 2022
News | ASTRO

August 12, 2022 — The American Society for Radiation Oncology (ASTRO) today expressed its support for President Joseph R ...

Time August 12, 2022
News | Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

Time August 10, 2022
News | Prostate Cancer

August 9, 2022 — Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD ...

Time August 09, 2022
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
Subscribe Now